T1	tradename 104 111	KADCYLA
T3	tradename 174 182	KADCYLA.
T5	tradename 184 191	KADCYLA
T7	nanoparticle 194 220	ado-trastuzumab emtansine)
T9	routeofadministration 240 251	intravenous
T11	adversereaction 295 309	HEPATOTOXICITY
T13	adversereaction 311 327	CARDIAC TOXICITY
T15	adversereaction 329 350	EMBRYO-FETAL TOXICITY
T17	tradename 432 439	KADCYLA
T19	adversereaction 472 486	Hepatotoxicity
T21	adversereaction 488 501	liver failure
T23	adversereaction 506 511	death
T25	tradename 529 544	KADCYLA-treated
T27	tradename 710 717	KADCYLA
T29	adversereaction 730 778	reductions in left ventricular ejection fraction
T31	adversereaction 904 915	fetal harm.
T33	tradename 1415 1422	KADCYLA
T35	chemoclass 1428 1441	HER2-targeted
T37	chemoclass 1455 1476	microtubule inhibitor
T39	indication 1552 1565	HER2-positive
T41	indication 1567 1591	metastatic breast cancer
T43	routeofadministration 1940 1951	intravenous
T45	routeofadministration 1992 2003	intravenous
T47	tradename 2085 2092	KADCYLA
T49	dose 2096 2105	3.6 mg/kg
T51	routeofadministration 2119 2130	intravenous
T53	frequency 2140 2153	every 3 weeks
T55	frequency 2155 2168	21-day cycle)
T57	tradename 2239 2246	KADCYLA
T59	dose 2269 2279	3.6 mg/kg.
T61	tradename 2299 2306	KADCYLA
T63	adversereaction 2369 2395	infusion-related reactions
T65	adversereaction 2397 2411	hepatotoxicity
T67	adversereaction 2413 2449	left ventricular cardiac dysfunction
T69	adversereaction 2451 2467	thrombocytopenia
T71	adversereaction 2469 2487	pulmonary toxicity
T73	adversereaction 2491 2513	peripheral neuropathy)
T75	tradename 2598 2606	KADCYLA.
T77	adversereaction 2957 2976	Pulmonary Toxicity:
T79	tradename 3001 3008	KADCYLA
T81	adversereaction 3090 3116	Infusion-Related Reactions
T83	adversereaction 3118 3145	Hypersensitivity Reactions:
T85	adversereaction 3221 3247	infusion-related reactions
T87	adversereaction 3251 3277	hypersensitivity reactions
T89	tradename 3388 3395	KADCYLA
T91	adversereaction 3417 3443	infusion-related reaction.
T93	adversereaction 3461 3472	Hemorrhage:
T95	adversereaction 3488 3498	hemorrhage
T97	adversereaction 3811 3828	Thrombocytopenia:
T99	tradename 3867 3874	KADCYLA
T101	adversereaction 3938 3952	Neurotoxicity:
T103	adversereaction 4039 4074	Grade 3 or 4 peripheral neuropathy.
T105	tradename 4333 4340	KADCYLA
T107	adversereaction 4371 4378	fatigue
T109	adversereaction 4380 4386	nausea
T111	adversereaction 4388 4408	musculoskeletal pain
T113	adversereaction 4410 4420	hemorrhage
T115	adversereaction 4422 4438	thrombocytopenia
T117	adversereaction 4440 4448	headache
T119	adversereaction 4450 4473	increased transaminases
T121	adversereaction 4475 4487	constipation
T123	adversereaction 4492 4502	epistaxis.
T125	company 4557 4566	Genentech
T127	tradename 4772 4779	KADCYLA
T129	adversereaction 5392 5406	Hepatotoxicity
T131	adversereaction 5407 5408	5
T133	adversereaction 5411 5439	Left Ventricular Dysfunction
T135	adversereaction 5440 5441	5
T137	adversereaction 5444 5465	Embryo-Fetal Toxicity
T139	adversereaction 5466 5467	5
T141	adversereaction 5470 5488	Pulmonary Toxicity
T143	adversereaction 5489 5490	5
T145	adversereaction 5493 5519	Infusion Related Reactions
T147	adversereaction 5521 5547	Hypersensitivity Reactions
T149	adversereaction 5548 5549	5
T151	adversereaction 5552 5562	Hemorrhage
T153	adversereaction 5563 5564	5
T155	adversereaction 5567 5583	Thrombocytopenia
T157	adversereaction 5584 5585	5
T159	adversereaction 5588 5601	Neurotoxicity
T161	adversereaction 5602 5603	5
T163	indication 6308 6332	Metastatic Breast Cancer
T165	indication 6333 6335	15
T167	tradename 6517 6524	KADCYLA
T169	adversereaction 6560 6574	HEPATOTOXICITY
T171	adversereaction 6576 6592	CARDIAC TOXICITY
T173	adversereaction 6594 6615	EMBRYO-FETAL TOXICITY
T175	adversereaction 6618 6633	Hepatotoxicity:
T177	adversereaction 6644 6658	hepatotoxicity
T179	adversereaction 6688 6701	liver failure
T181	adversereaction 6707 6712	death
T183	tradename 6738 6746	KADCYLA.
T185	tradename 6812 6819	KADCYLA
T187	tradename 6848 6855	KADCYLA
T189	tradename 6890 6897	KADCYLA
T191	adversereaction 6988 7005	Cardiac Toxicity:
T193	tradename 7007 7014	KADCYLA
T195	adversereaction 7042 7090	reductions in left ventricular ejection fraction
T197	tradename 7187 7195	KADCYLA.
T199	adversereaction 7296 7318	Embryo-Fetal Toxicity:
T201	tradename 7332 7339	KADCYLA
T203	adversereaction 7354 7372	embryo-fetal death
T205	adversereaction 7376 7390	birth defects.
T207	tradename 7510 7517	KADCYLA
T209	indication 7587 7600	HER2-positive
T211	indication 7602 7626	metastatic breast cancer
T213	tradename 7966 7973	KADCYLA
T215	dose 7977 7986	3.6 mg/kg
T217	routeofadministration 7999 8010	intravenous
T219	frequency 8020 8033	every 3 weeks
T221	frequency 8035 8048	21-day cycle)
T223	tradename 8120 8127	KADCYLA
T225	dose 8150 8160	3.6 mg/kg.
T227	tradename 8180 8187	KADCYLA
T229	tradename 8815 8822	KADCYLA
T231	tradename 9243 9250	KADCYLA
T233	adversereaction 9310 9336	infusion-related reaction.
T235	tradename 9363 9370	KADCYLA
T237	adversereaction 9392 9418	infusion-related reactions
T239	adversereaction 9473 9502	increased serum transaminases
T241	adversereaction 9504 9522	hyperbilirubinemia
T243	adversereaction 9524 9552	left ventricular dysfunction
T245	adversereaction 9554 9570	thrombocytopenia
T247	adversereaction 9572 9590	pulmonary toxicity
T249	adversereaction 9594 9615	peripheral neuropathy
T251	tradename 9699 9706	KADCYLA
T253	dose 9870 9879	3.6 mg/kg
T255	dose 9901 9908	3 mg/kg
T257	dose 9931 9940	2.4 mg/kg
T259	dose 9941 9952	Requirement
T261	adversereaction 10003 10017	Hepatotoxicity
T263	tradename 10082 10089	KADCYLA
T265	adversereaction 10120 10134	hepatotoxicity
T267	adversereaction 10148 10180	increases in serum transaminases
T269	adversereaction 10188 10206	hyperbilirubinemia
T271	adversereaction 10271 10310	Increased Serum Transaminases (AST/ALT)
T273	tradename 10464 10471	KADCYLA
T275	tradename 10572 10580	KADCYLA.
T277	adversereaction 10710 10728	Hyperbilirubinemia
T279	tradename 10854 10861	KADCYLA
T281	tradename 10967 10974	KADCYLA
T283	tradename 11083 11091	KADCYLA.
T285	tradename 11116 11123	KADCYLA
T287	tradename 11255 11262	KADCYLA
T289	tradename 11659 11666	KADCYLA
T291	tradename 11688 11696	KADCYLA.
T293	tradename 11781 11789	KADCYLA.
T295	tradename 11808 11816	KADCYLA.
T297	tradename 11935 11943	KADCYLA.
T299	tradename 11968 11976	KADCYLA.
T301	tradename 12041 12049	KADCYLA.
T303	tradename 12448 12455	KADCYLA
T305	tradename 12583 12590	KADCYLA
T307	tradename 12770 12777	KADCYLA
T309	tradename 12947 12954	KADCYLA
T311	tradename 13263 13270	KADCYLA
T313	nanoparticle 13272 13298	ado-trastuzumab emtansine)
T315	tradename 13349 13356	KADCYLA
T317	routeofadministration 13363 13374	intravenous
T319	routeofadministration 13480 13491	intravenous
T321	tradename 13521 13528	KADCYLA
T323	tradename 14033 14040	KADCYLA
T325	tradename 14102 14109	KADCYLA
T327	tradename 14744 14751	KADCYLA
T329	tradename 14854 14861	KADCYLA
T331	tradename 15031 15038	KADCYLA
T333	tradename 15130 15137	KADCYLA
T335	tradename 15393 15400	KADCYLA
T337	nanoparticle 15797 15823	ado-trastuzumab emtansine.
T339	tradename 16070 16077	KADCYLA
T341	tradename 16297 16305	KADCYLA.
T343	tradename 16511 16518	KADCYLA
T345	tradename 16547 16554	KADCYLA
T347	tradename 16719 16726	KADCYLA
T349	tradename 16872 16879	KADCYLA
T351	tradename 16988 16995	KADCYLA
T353	tradename 17159 17166	KADCYLA
T355	tradename 17967 17974	KADCYLA
T357	adversereaction 18025 18053	Left Ventricular Dysfunction
T359	adversereaction 18054 18062	Patients
T361	tradename 18076 18083	KADCYLA
T363	adversereaction 18120 18149	left ventricular dysfunction.
T365	tradename 18226 18234	KADCYLA.
T367	tradename 18337 18352	KADCYLA-treated
T369	tradename 18497 18504	KADCYLA
T371	tradename 18652 18659	KADCYLA
T373	tradename 18889 18896	KADCYLA
T375	tradename 18980 18987	KADCYLA
T377	adversereaction 19315 19336	Embryo-Fetal Toxicity
T379	tradename 19339 19346	KADCYLA
T381	tradename 19462 19469	KADCYLA
T383	nanoparticle 19570 19596	ado-trastuzumab emtansine.
T385	tradename 19666 19673	KADCYLA
T387	tradename 19879 19886	KADCYLA
T389	adversereaction 19913 19934	embryo-fetal toxicity
T391	tradename 19972 19979	KADCYLA
T393	tradename 20057 20064	KADCYLA
T395	tradename 20111 20118	KADCYLA
T397	tradename 20270 20278	KADCYLA.
T399	adversereaction 20312 20330	embryo-fetal death
T401	adversereaction 20335 20348	birth defects
T403	tradename 20517 20524	KADCYLA
T405	tradename 20607 20614	KADCYLA
T407	tradename 20661 20668	KADCYLA
T409	adversereaction 20967 20985	Pulmonary Toxicity
T411	adversereaction 20986 20991	Cases
T413	adversereaction 20995 21026	interstitial lung disease (ILD)
T415	adversereaction 21038 21049	pneumonitis
T417	adversereaction 21067 21102	acute respiratory distress syndrome
T419	tradename 21163 21171	KADCYLA.
T421	adversereaction 21174 21185	Pneumonitis
T423	adversereaction 21278 21298	grade 3 pneumonitis.
T425	adversereaction 21328 21335	dyspnea
T427	adversereaction 21337 21342	cough
T429	adversereaction 21344 21351	fatigue
T431	adversereaction 21357 21379	pulmonary infiltrates.
T433	adversereaction 21512 21523	pneumonitis
T435	tradename 21605 21612	KADCYLA
T437	adversereaction 21640 21643	ILD
T439	adversereaction 21647 21659	pneumonitis.
T441	adversereaction 21782 21801	pulmonary toxicity.
T443	tradename 21878 21885	KADCYLA
T445	tradename 22044 22051	KADCYLA
T447	adversereaction 22092 22118	Infusion-related reactions
T449	adversereaction 22177 22185	flushing
T451	adversereaction 22187 22193	chills
T453	adversereaction 22195 22202	pyrexia
T455	adversereaction 22204 22211	dyspnea
T457	adversereaction 22213 22224	hypotension
T459	adversereaction 22226 22234	wheezing
T461	adversereaction 22236 22248	bronchospasm
T463	adversereaction 22254 22265	tachycardia
T465	tradename 22307 22315	KADCYLA.
T467	tradename 22408 22415	KADCYLA
T469	tradename 22580 22587	KADCYLA
T471	tradename 22650 22657	KADCYLA
T473	tradename 22991 22999	KADCYLA.
T475	adversereaction 23116 23126	Hemorrhage
T477	adversereaction 23127 23132	Cases
T479	tradename 23279 23287	Kadcyla.
T481	tradename 23435 23450	KADCYLA-treated
T483	tradename 23579 23594	KADCYLA-treated
T485	adversereaction 24012 24028	Thrombocytopenia
T487	adversereaction 24029 24045	Thrombocytopenia
T489	adversereaction 24050 24074	decreased platelet count
T491	tradename 24111 24118	KADCYLA
T493	tradename 24456 24463	KADCYLA
T495	adversereaction 24608 24624	thrombocytopenia
T497	tradename 24642 24657	KADCYLA-treated
T499	adversereaction 24789 24805	thrombocytopenia
T501	tradename 24823 24838	KADCYLA-treated
T503	adversereaction 24955 24971	thrombocytopenia
T505	tradename 24989 25004	KADCYLA-treated
T507	tradename 25118 25125	KADCYLA
T509	tradename 25144 25151	KADCYLA
T511	tradename 25198 25205	KADCYLA
T513	tradename 25411 25418	KADCYLA
T515	adversereaction 25537 25553	thrombocytopenia
T517	co-administereddrug 25589 25603	anti-coagulant
T519	tradename 25664 25672	KADCYLA.
T521	adversereaction 25681 25694	Neurotoxicity
T523	adversereaction 25695 25716	Peripheral neuropathy
T525	tradename 25798 25805	KADCYLA
T527	adversereaction 25964 25985	peripheral neuropathy
T529	tradename 26003 26018	KADCYLA-treated
T531	tradename 26189 26204	KADCYLA-treated
T533	tradename 26272 26279	KADCYLA
T535	adversereaction 26353 26374	peripheral neuropathy
T537	adversereaction 26500 26513	neurotoxicity
T539	tradename 26690 26697	KADCYLA
T541	company 26980 26984	Dako
T543	company 27079 27083	Dako
T545	tradename 27641 27648	KADCYLA
T547	adversereaction 27828 27836	erythema
T549	adversereaction 27838 27848	tenderness
T551	adversereaction 27850 27865	skin irritation
T553	adversereaction 27867 27871	pain
T555	adversereaction 27876 27906	swelling at the infusion site.
T557	tradename 27932 27939	KADCYLA
T559	adversereaction 28198 28212	Hepatotoxicity
T561	adversereaction 28250 28278	Left Ventricular Dysfunction
T563	adversereaction 28317 28338	Embryo-Fetal Toxicity
T565	adversereaction 28376 28394	Pulmonary Toxicity
T567	adversereaction 28432 28458	Infusion-Related Reactions
T569	adversereaction 28460 28486	Hypersensitivity Reactions
T571	adversereaction 28524 28534	Hemorrhage
T573	adversereaction 28572 28588	Thrombocytopenia
T575	adversereaction 28627 28640	Neurotoxicity
T577	tradename 28999 29006	KADCYLA
T579	indication 29063 29102	HER2-positive metastatic breast cancer.
T581	tradename 29210 29217	KADCYLA
T583	adversereaction 29223 29230	fatigue
T585	adversereaction 29232 29238	nausea
T587	adversereaction 29240 29260	musculoskeletal pain
T589	adversereaction 29262 29272	hemorrhage
T591	adversereaction 29274 29290	thrombocytopenia
T593	adversereaction 29292 29300	headache
T595	adversereaction 29302 29325	increased transaminases
T597	adversereaction 29327 29339	constipation
T599	adversereaction 29344 29354	epistaxis.
T601	indication 29419 29457	HER2-positive metastatic breast cancer
T603	tradename 29567 29574	KADCYLA
T605	tradename 29683 29698	KADCYLA-treated
T607	tradename 29895 29910	KADCYLA-treated
T609	tradename 30025 30032	KADCYLA
T611	tradename 30129 30136	KADCYLA
T613	tradename 30346 30353	KADCYLA
T615	adversereaction 30370 30386	thrombocytopenia
T617	adversereaction 30391 30415	increased transaminases.
T619	tradename 30454 30461	KADCYLA
T621	tradename 30573 30580	KADCYLA
T623	adversereaction 30619 30635	thrombocytopenia
T625	adversereaction 30637 30660	increased transaminases
T627	adversereaction 30666 30688	peripheral neuropathy.
T629	tradename 30757 30764	KADCYLA
T631	tradename 30845 30852	KADCYLA
T633	adversereaction 30887 30898	neutropenia
T635	adversereaction 30900 30916	thrombocytopenia
T637	adversereaction 30918 30928	leukopenia
T639	adversereaction 30930 30937	fatigue
T641	adversereaction 30939 30962	increased transaminases
T643	adversereaction 30967 30975	pyrexia.
T645	tradename 31035 31050	KADCYLA-treated
T647	tradename 31190 31197	KADCYLA
T649	adversereaction 31248 31254	nausea
T651	adversereaction 31256 31263	fatigue
T653	adversereaction 31265 31285	musculoskeletal pain
T655	adversereaction 31287 31297	hemorrhage
T657	adversereaction 31299 31315	thrombocytopenia
T659	adversereaction 31317 31340	increased transaminases
T661	adversereaction 31342 31350	headache
T663	adversereaction 31356 31369	constipation.
T665	adversereaction 31456 31472	thrombocytopenia
T667	adversereaction 31474 31497	increased transaminases
T669	adversereaction 31499 31505	anemia
T671	adversereaction 31507 31518	hypokalemia
T673	adversereaction 31520 31541	peripheral neuropathy
T675	adversereaction 31546 31554	fatigue.
T677	tradename 31629 31636	KADCYLA
T679	tradename 31739 31746	KADCYLA
T681	dose 31748 31758	3.6 mg/kg)
T683	dose 31794 31802	1250 mg)
T685	dose 31819 31830	2000 mg/m2)
T687	adversereaction 31957 31968	Neutropenia
T689	adversereaction 31985 31991	Anemia
T691	adversereaction 32010 32026	Thrombocytopenia
T693	adversereaction 32063 32091	Left ventricular dysfunction
T695	adversereaction 32122 32143	Lacrimation increased
T697	adversereaction 32156 32163	Dry eye
T699	adversereaction 32176 32190	Vision blurred
T701	adversereaction 32203 32217	Conjunctivitis
T703	adversereaction 32257 32266	Dyspepsia
T705	adversereaction 32282 32292	Stomatitis
T707	adversereaction 32311 32320	Dry Mouth
T709	adversereaction 32336 32350	Abdominal pain
T711	adversereaction 32369 32377	Vomiting
T713	adversereaction 32396 32404	Diarrhea
T715	adversereaction 32424 32436	Constipation
T717	adversereaction 32453 32459	Nausea
T719	adversereaction 32516 32532	Peripheral edema
T721	adversereaction 32547 32553	Chills
T723	adversereaction 32566 32573	Pyrexia
T725	adversereaction 32591 32599	Asthenia
T727	adversereaction 32618 32625	Fatigue
T729	adversereaction 32669 32702	Nodular regenerative hyperplasia*
T731	tradename 32768 32775	KADCYLA
T733	dose 32777 32787	3.6 mg/kg)
T735	dose 32823 32831	1250 mg)
T737	dose 32848 32859	2000 mg/m2)
T739	adversereaction 33002 33023	Drug hypersensitivity
T741	adversereaction 33071 33096	Infusion-related reaction
T743	adversereaction 33137 33160	Urinary tract infection
T745	adversereaction 33190 33226	Blood alkaline phosphatase increased
T747	adversereaction 33244 33267	Increased transaminases
T749	adversereaction 33323 33334	Hypokalemia
T751	adversereaction 33401 33408	Myalgia
T753	adversereaction 33424 33434	Arthralgia
T755	adversereaction 33450 33470	Musculoskeletal pain
T757	adversereaction 33514 33523	Dysgeusia
T759	adversereaction 33539 33548	Dizziness
T761	adversereaction 33567 33588	Peripheral neuropathy
T763	adversereaction 33608 33616	Headache
T765	adversereaction 33657 33665	Insomnia
T767	adversereaction 33733 33744	Pneumonitis
T769	adversereaction 33755 33762	Dyspnea
T771	adversereaction 33780 33785	Cough
T773	adversereaction 33804 33813	Epistaxis
T775	adversereaction 33869 33877	Pruritus
T777	adversereaction 33892 33896	Rash
T779	adversereaction 33932 33942	Hemorrhage
T781	adversereaction 33961 33973	Hypertension
T783	tradename 34158 34165	KADCYLA
T785	dose 34167 34177	3.6 mg/kg)
T787	dose 34190 34198	1250 mg)
T789	dose 34215 34226	2000 mg/m2)
T791	indication 34491 34529	HER2-positive metastatic breast cancer
T793	tradename 34562 34569	KADCYLA
T795	tradename 34695 34703	KADCYLA.
T797	tradename 34840 34848	KADCYLA.
T799	tradename 34861 34868	KADCYLA
T801	tradename 34928 34935	KADCYLA
T803	tradename 35003 35010	KADCYLA
T805	tradename 35116 35123	KADCYLA
T807	tradename 35210 35217	KADCYLA
T809	tradename 35284 35291	KADCYLA
T811	tradename 35728 35735	KADCYLA
T813	tradename 35838 35845	KADCYLA
T815	tradename 35941 35948	KADCYLA
T817	activeingredient 36003 36006	DM1
T819	tradename 36035 36042	KADCYLA
T821	tradename 36315 36322	KADCYLA
T823	activeingredient 36381 36384	DM1
T825	tradename 36573 36580	KADCYLA
T827	tradename 36787 36794	KADCYLA
T829	tradename 37006 37013	KADCYLA
T831	tradename 37129 37136	KADCYLA
T833	nanoparticle 37236 37262	ado-trastuzumab emtansine.
T835	tradename 37296 37303	KADCYLA
T837	activeingredient 37321 37325	DM1)
T839	tradename 37422 37429	KADCYLA
T841	tradename 37513 37520	KADCYLA
T843	tradename 37567 37574	KADCYLA
T845	tradename 37716 37723	KADCYLA
T847	tradename 37768 37776	KADCYLA.
T849	tradename 37781 37788	KADCYLA
T851	tradename 37871 37878	KADCYLA
T853	tradename 37925 37932	KADCYLA
T855	company 37969 37978	Genentech
T857	nanoparticle 38883 38909	ado-trastuzumab emtansine.
T859	activeingredient 38912 38915	DM1
T861	tradename 38944 38951	KADCYLA
T863	activeingredient 38986 38989	DM1
T865	dose 39213 39221	25 mg/kg
T867	tradename 39606 39613	KADCYLA
T869	dose 39857 39865	25 mg/kg
T871	tradename 39902 39910	KADCYLA)
T873	tradename 40043 40050	KADCYLA
T875	tradename 40124 40131	KADCYLA
T877	tradename 40283 40290	KADCYLA
T879	tradename 40399 40406	KADCYLA
T881	nanoparticle 40929 40954	ado-trastuzumab emtansine
T883	tradename 41030 41037	KADCYLA
T885	adversereaction 41048 41065	embryo-fetal harm
T887	tradename 41256 41263	KADCYLA
T889	tradename 41308 41315	KADCYLA
T891	tradename 41361 41368	KADCYLA
T893	tradename 41453 41460	KADCYLA
T895	tradename 41507 41514	KADCYLA
T897	company 41551 41560	Genentech
T899	tradename 41874 41881	KADCYLA
T901	tradename 42055 42062	KADCYLA
T903	activeingredient 42467 42470	DM1
T905	nanoparticle 42564 42589	ado-trastuzumab emtansine
T907	tradename 42683 42691	KADCYLA.
T909	tradename 42726 42733	KADCYLA
T911	tradename 42936 42943	KADCYLA
T913	dose 42947 42954	6 mg/kg
T915	tradename 43056 43063	KADCYLA
T917	tradename 43102 43109	KADCYLA
T919	nanoparticle 43111 43137	ado-trastuzumab emtansine)
T921	chemoclass 43143 43156	HER2-targeted
T923	nanoparticle 43157 43186	antibody-drug conjugate (ADC)
T925	corecomposition 43202 43226	humanized anti-HER2 IgG1
T927	corecomposition 43228 43239	trastuzumab
T929	chemoclass 43266 43288	microtubule inhibitory
T931	activeingredient 43294 43323	DM1 (a maytansine derivative)
T933	surfacecoating 43339 43410	thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate).
T935	activeingredient 43442 43443	1
T937	corecomposition 43468 43479	trastuzumab
T939	activeingredient 43633 43636	DM1
T941	nanoparticle 43683 43708	Ado-trastuzumab emtansine
T943	activeingredient 43736 43739	DM1
T945	nanoparticle 43765 43790	Ado-trastuzumab emtansine
T947	activeingredient 43864 43867	DM1
T949	activeingredient 43947 43950	DM1
T951	tradename 43994 44001	KADCYLA
T953	nanoparticle 44003 44029	ado-trastuzumab emtansine)
T955	nanoparticle 44159 44185	ado-trastuzumab emtansine.
T957	nanoparticle 44244 44269	ado-trastuzumab emtansine
T959	inactiveingredient 44282 44296	polysorbate 20
T961	inactiveingredient 44312 44328	sodium succinate
T963	inactiveingredient 44342 44349	sucrose
T965	nanoparticle 44450 44475	ado-trastuzumab emtansine
T967	routeofadministration 44495 44506	intravenous
T969	nanoparticle 44587 44612	Ado-trastuzumab emtansine
T971	chemoclass 44618 44631	HER2-targeted
T973	nanoparticle 44632 44656	antibody-drug conjugate.
T975	corecomposition 44679 44703	humanized anti-HER2 IgG1
T977	corecomposition 44705 44717	trastuzumab.
T979	activeingredient 44749 44752	DM1
T981	chemoclass 44759 44781	microtubule inhibitor.
T983	nanoparticle 44836 44861	ado-trastuzumab emtansine
T985	activeingredient 44982 44986	DM1-
T987	activeingredient 45033 45036	DM1
T989	nanoparticle 45224 45249	ado-trastuzumab emtansine
T991	tradename 45494 45501	KADCYLA
T993	nanoparticle 45588 45613	ado-trastuzumab emtansine
T995	activeingredient 45945 45948	DM1
T997	tradename 45997 46004	KADCYLA
T999	activeingredient 46084 46087	DM1
T1001	activeingredient 46162 46165	DM1
T1003	tradename 46189 46196	KADCYLA
T1005	cmax 46216 46232	83.4 (16.5) /mL
T1007	cmax 46237 46254	4.61 (1.61) ng/mL
T1009	activeingredient 46302 46305	DM1
T1011	activeingredient 46350 46353	DM1
T1013	volumeofdistribution 46489 46496	3.13 L.
T1015	activeingredient 46541 46544	DM1
T1017	tradename 46578 46585	KADCYLA
T1019	activeingredient 46622 46625	DM1
T1021	nanoparticle 46702 46727	ado-trastuzumab emtansine
T1023	activeingredient 46746 46747	1
T1025	activeingredient 46759 46760	1
T1027	activeingredient 46766 46769	DM1
T1029	routeofadministration 46871 46882	intravenous
T1031	tradename 46895 46902	KADCYLA
T1033	clearance 46933 46943	0.68 L/day
T1035	eliminationhalflife 46999 47006	4 days.
T1037	tradename 47028 47035	KADCYLA
T1039	routeofadministration 47074 47085	intravenous
T1041	frequency 47095 47109	every 3 weeks.
T1043	nanoparticle 47393 47418	ado-trastuzumab emtansine
T1045	nanoparticle 47488 47513	ado-trastuzumab emtansine
T1047	tradename 47645 47652	KADCYLA
T1049	dose 47706 47715	3.6 mg/kg
T1051	nanoparticle 48530 48556	ado-trastuzumab emtansine.
T1053	tradename 48625 48632	KADCYLA
T1055	dose 48634 48643	3.6 mg/kg
T1057	indication 48748 48787	HER2-positive metastatic breast cancer.
T1059	nanoparticle 49017 49043	ado-trastuzumab emtansine.
T1061	activeingredient 49045 49048	DM1
T1063	activeingredient 49207 49210	DM1
T1065	tradename 49243 49251	KADCYLA.
T1067	activeingredient 49254 49257	DM1
T1069	tradename 49382 49389	KADCYLA
T1071	nanoparticle 49459 49484	ado-trastuzumab emtansine
T1073	dose 49654 49662	60 mg/kg
T1075	nanoparticle 49862 49887	ado-trastuzumab emtansine
T1077	frequency 49893 49910	every three weeks
T1079	duration 49915 49923	12 weeks
T1081	dose 49947 49955	30 mg/kg
T1083	nanoparticle 50301 50326	ado-trastuzumab emtansine
T1085	dose 50333 50341	30 mg/kg
T1087	activeingredient 50640 50643	DM1
T1089	adversereaction 50677 50690	neurotoxicity
T1091	indication 50755 50779	Metastatic Breast Cancer
T1093	tradename 50796 50803	KADCYLA
T1095	indication 50886 50899	HER2-positive
T1097	indication 50934 50959	metastatic breast cancer.
T1099	tradename 51429 51437	KADCYLA.
T1101	tradename 51712 51719	KADCYLA
T1103	routeofadministration 51730 51743	intravenously
T1105	dose 51747 51756	3.6 mg/kg
T1107	frequency 51771 51784	21-day cycle.
T1109	dose 51817 51824	1250 mg
T1111	frequency 51824 51828	/day
T1113	routeofadministration 51829 51835	orally
T1115	frequency 51836 51848	once per day
T1117	frequency 51854 51866	21-day cycle
T1119	dose 51904 51914	1000 mg/m2
T1121	routeofadministration 51915 51921	orally
T1123	frequency 51922 51933	twice daily
T1125	frequency 51952 51965	21-day cycle.
T1127	tradename 51994 52001	KADCYLA
T1129	tradename 52212 52219	KADCYLA
T1131	tradename 54488 54503	KADCYLA-treated
T1133	tradename 54710 54725	KADCYLA-treated
T1135	tradename 55056 55063	KADCYLA
T1137	tradename 55368 55375	KADCYLA
T1139	tradename 55572 55579	KADCYLA
T1141	tradename 55694 55701	KADCYLA
T1143	tradename 56938 56945	KADCYLA
T1145	tradename 58522 58529	KADCYLA
T1147	nanoparticle 58531 58557	ado-trastuzumab emtansine)
T1149	adversereaction 58980 58999	severe liver injury
T1151	adversereaction 59090 59105	acute hepatitis
T1153	adversereaction 59114 59120	nausea
T1155	adversereaction 59122 59130	vomiting
T1157	adversereaction 59132 59146	abdominal pain
T1159	adversereaction 59159 59178	RUQ abdominal pain)
T1161	adversereaction 59180 59188	jaundice
T1163	adversereaction 59190 59200	dark urine
T1165	adversereaction 59202 59222	generalized pruritus
T1167	adversereaction 59224 59232	anorexia
T1169	adversereaction 59370 59412	new onset or worsening shortness of breath
T1171	adversereaction 59414 59419	cough
T1173	adversereaction 59421 59448	swelling of the ankles/legs
T1175	adversereaction 59450 59462	palpitations
T1177	adversereaction 59464 59509	weight gain of more than 5 pounds in 24 hours
T1179	adversereaction 59511 59545	dizziness or loss of consciousness
T1181	tradename 59650 59657	KADCYLA
T1183	adversereaction 59703 59721	embryo-fetal death
T1185	adversereaction 59725 59738	birth defects
T1187	tradename 59869 59876	KADCYLA
T1189	tradename 59921 59928	KADCYLA
T1191	tradename 60012 60019	KADCYLA
T1193	tradename 60058 60065	KADCYLA
T1195	tradename 60202 60209	KADCYLA
T1197	tradename 60262 60269	KADCYLA
T1199	tradename 60316 60323	KADCYLA
T1201	tradename 60448 60455	KADCYLA
T1203	tradename 60632 60639	KADCYLA
T1205	nanoparticle 60642 60668	ado-trastuzumab emtansine]
T1207	company 60687 60696	Genentech
T1209	company 60698 60702	Inc.
T1211	company 60719 60730	Roche Group
T1213	fdaapprovaldate 60826 60839	February 2013
T1215	tradename 60844 60851	KADCYLA
T1217	company 60870 60879	Genentech
T1219	company 60881 60885	Inc.
T1221	company 60892 60901	Genentech
T1223	company 60903 60907	Inc.
